or Try an Advanced Search...

    Technical Analysis for NRSNW - NeuroSense Therapeutics Ltd. - warrant

    Grade Last Price % Change Price Change
    C 0.25 -19.35% -0.06
    NRSNW closed down 19.35 percent on Tuesday, April 16, 2024, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical NRSNW trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Crossed Above 50 DMA Bullish -19.35%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -19.35%
    NR7 Range Contraction -19.35%
    Older End-of-Day Signals for NRSNW ...

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NRSNW Chart by TradingView
    Basic chart:

    Profile

    NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Senescence Treatment Of Alzheimer's Disease Neurodegenerative Disease Clinical Neuroscience

    Is NRSNW a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 12 NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
    Apr 10 NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
    Apr 9 NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
    Feb 21 NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
    Jan 30 NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
    Jan 9 NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
    Nov 28 NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
    Nov 9 NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
    Nov 6 NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
    Nov 1 NeuroSense Therapeutics to Participate in BIO-Europe Fall
    See more NRSNW news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.64
    52 Week Low 0.073
    Average Volume 11,129
    200-Day Moving Average 0.23
    50-Day Moving Average 0.29
    20-Day Moving Average 0.36
    10-Day Moving Average 0.37
    Average True Range 0.10
    RSI (14) 44.13
    ADX 26.99
    +DI 13.60
    -DI 19.24
    Chandelier Exit (Long, 3 ATRs) 0.26
    Chandelier Exit (Short, 3 ATRs) 0.52
    Upper Bollinger Bands 0.53
    Lower Bollinger Band 0.19
    Percent B (%b) 0.19
    BandWidth 95.90
    MACD Line 0.01
    MACD Signal Line 0.03
    MACD Histogram -0.0219
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.25
    Resistance 3 (R3) 0.25 0.25 0.25
    Resistance 2 (R2) 0.25 0.25 0.25 0.25
    Resistance 1 (R1) 0.25 0.25 0.25 0.25 0.25
    Pivot Point 0.25 0.25 0.25 0.25 0.25
    Support 1 (S1) 0.25 0.25 0.25 0.25 0.25
    Support 2 (S2) 0.25 0.25 0.25 0.25
    Support 3 (S3) 0.25 0.25 0.25
    Support 4 (S4) 0.25